November 2022
-
11.10.2022 Corporate Partnerships Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations
October 2022
-
10.04.2022 Corporate Partnerships Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
September 2022
-
09.20.2022 Corporate Partnerships CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
June 2022
-
06.21.2022 Corporate Partnerships Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time
May 2022
-
05.20.2022 Corporate Partnerships NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.
April 2022
-
04.27.2022 Corporate Partnerships Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer -
04.26.2022 Partnerships Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
February 2022
-
02.14.2022 Partnerships Pfizer joins the Open Targets consortium
January 2022
-
01.31.2022 Partnerships Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program -
01.18.2022 Partnerships Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform -
01.11.2022 Partnerships Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
December 2021
-
12.16.2021 Partnerships Anaveon to raise CHF 110 million in oversubscribed Series B financing